脑膜瘤疗效评估:一维、二维和体积标准用于治疗反应和肿瘤进展
这项回顾性多中心研究评估了93例接受药物治疗的复发性脑膜瘤患者的临床和影像数据,比较一维、二维和体积测量标准与总生存期(OS)的关联。结果显示,6个月和12个月时体积增加40%和一维增加10 mm与OS关联最强(HR分别为2.58和3.24,p<0.01)。作者认为体积标准与OS的关联强于一维(RECIST 1.1)和二维(RANO)标准,但差异仅为中等程度。
要点
- 6个月和12个月时体积增加40%与OS关联最强(HR=2.58,p<0.01)。
- 6个月和12个月时一维增加10 mm与OS关联最强(HR=3.24,p<0.01)。
- 一维、二维和体积标准的观察者间一致性仅为中等(kappa分别为0.49、0.46、0.52)。
核心结论
- 与一维(RECIST 1.1)和二维(RANO)方法相比,用于肿瘤进展的体积标准与OS的关联更强,但差异仅为中等程度。
- 所有3种方法的观察者间变异性均为中等。
- 需要在独立患者队列中进一步验证这些发现。
研究设计与样本
- 回顾性多中心研究,评估93例接受药物治疗的复发性脑膜瘤患者的临床和影像数据。
- 比较治疗前和治疗后MRI上强化肿瘤的一维、二维和体积测量,评估时间点为治疗开始后6个月和12个月。
- 采用Cox比例风险模型检验每种影像标准与OS的关系。
主要发现
- 患者队列中位年龄为51岁(范围12-88),包括14例WHO I级、53例WHO II级和26例WHO III级脑膜瘤。
- 6个月和12个月时体积增加40%与OS关联最强(HR=2.58,p<0.01)。
- 6个月和12个月时一维增加10 mm与OS关联最强(HR=3.24,p<0.01)。
- 将体积变化阈值设定为高于40%与生存无关。
- 一维、二维和体积标准的观察者间一致性仅为中等(kappa分别为0.49、0.46、0.52)。
关键数值与推荐
- 体积增加40%(6个月和12个月)与OS关联:HR=2.58,p<0.01。
- 一维增加10 mm(6个月和12个月)与OS关联:HR=3.24,p<0.01。
- 观察者间一致性:一维kappa=0.49,二维kappa=0.46,体积kappa=0.52。
- 基于肿瘤尺寸缩小的标准与OS无关:P > 0.09。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要在独立患者队列中进一步验证这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Meningiomas are the most common primary brain tumors in adults. Due to their variable growth rates and irregular tumor shapes, response assessment in clinical trials remains challenging and no standard criteria have been defined. We evaluated 1D, 2D, and volume imaging criteria to assess whether a volumetric approach might be a superior surrogate for overall survival (OS). METHODS: In this retrospective multicenter study, we evaluated the clinical and imaging data of 93 patients with recurrent meningiomas treated with pharmacotherapy. One-dimensional (1D), 2D, and volumetric measurements of enhancing tumor on pre- and post-treatment MRI were compared at 6 and 12 months after treatment initiation. Cox proportional hazards models were used to examine the relationship between each imaging criterion and OS. RESULTS: The median age of the patient cohort is 51 years (range 12-88), with 14 World Health Organization (WHO) grade I, 53 WHO grade II, and 26 WHO grade III meningiomas. Volumetric increase of 40% and unidimensional increase by 10 mm at 6 months and 12 months provided the strongest association with overall survival (HR = 2.58 and 3.24 respectively, p<0.01). Setting a volume change threshold above 40% did not correlate with survival. The interobserver agreement of 1D, 2D, and volume criteria is only moderate (kappa = 0.49, 0.46, 0.52, respectively). None of the criteria based on tumor size reduction were associated with OS (P > 0.09). CONCLUSION: Compared with 1D (Response Evaluation Criteria In Solid Tumors 1.1) and 2D (Response Assessment in Neuro-Oncology) approaches, volumetric criteria for tumor progression has a stronger association with OS, although the differences were only modest. The interobserver variability is moderate for all 3 methods. Further validation of these findings in an independent patient cohort is needed.
引用
- Huang RY, Unadkat P, Bi WL, et al. Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progression. Neuro Oncol. 2019. PMID: 30085283. doi:10.1093/neuonc/noy126
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。